We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

BioVendor Group

BioVendor Group is an international group of biotechnology companies (BioVendor LM, BioVendor R&D, TestLine, ViennaLa... read more Featured Products: More products

Download Mobile App





Biovendor Group presents its CLIA, NGS, Microblot Array, microRNA and LAMP Product Lines at MEDICA 2021

By LabMedica International staff writers
Posted on 15 Nov 2021
BioVendor Group (Brno, Czech Republic) presented its CLIA, NGS, Microblot Array, microRNA and LAMP product lines at the 2021 edition of MEDICA, the world's largest trade fair for medical technology, held from 15 to 18 November in Düsseldorf, Germany.

BioVendor presented its newly-launched KleeYab fully automated analyzer, a highly flexible, fast and sensitive random access chemiluminescence platform that provides a unique approach to the use of different bead-based chemiluminescence technologies, offering superior assay performance and providing ease of use with cost containment. More...
The open platform system features a unique trigger cartridge technology that allows the use of both flash and glow detection technologies, along with unique stackable reaction cuvettes to eliminate system handling errors and reduce shipping and storage space.

BioVendor demonstrated its new Next Generation Sequencing (NGS) technology, fastGEN designed for examination of the mutation status of oncomarkers in samples. Its technology is based on ultra-deep sequencing of short amplicons obtained by a single polymerase chain reaction with special tagged hybrid primers. The fastGEN technology is simple, ultra-sensitive, specific and effective - it is perfectly adapted to diagnostics and offers new advantages for clinical material.

At MEDICA 2021, BioVendor also demonstrated its Microblot-Array (MBA), a new generation of a market-unique immunoblot array in a microtiter plate format. It is designed for efficient multiplex diagnostics, enabling the simultaneous detection of multiple markers which is time and cost-saving. The technology eliminates the limited capacity of traditional BLOT strips and opens the way to high throughput testing. Simple processing can be done manually or automatically using any open ELISA analyzers. Additionally, BioVendor presented its complete solution for microRNAs (miRNAs) and other short non-coding RNA sequences (sncRNA) projects, starting with isolation, followed by screening for proper targets and their final quantification. BioVendor also showcased its loop-mediated isothermal amplification (LAMP) assays which bring a novel approach for direct detection of target nucleic acids without the need of isolation step. The unique architecture of the LAMP method ensures its high sensitivity and specificity, and a tolerance for inhibitory substances.

Related Links:
BioVendor Group


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Manual Pipetting Aid
Pipette Controllers macro
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.